Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?
Around 90% of solid-tumor immunotherapy programs fail - many due to poor target selection. But what if we could eliminate the guesswork?
Instead of relying on predictions, 3T Biosciences are measuring real human T cell responses - using functional screening to find peptide-HLA targets that activate T cells effectively.
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.
